Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.
A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of AL2846 Capsules Combined With TQB2450 Injection Compared With Docetaxel Injection in Patients With Advanced Non-small Cell Lung Cancer Who Have Failed With Immunotherapy.
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This PHASE3 trial investigates Non-small Cell Lung Cancer and is currently actively recruiting participants. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE3
-
Feb 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE3
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baoding, China , Beijing, China , Binzhou, China , Changsha, China , Changzhi, China , Chengde, China , Chongqing, China , Daqing, China , Fuzhou, China , Guigang, China and 37 more locations